Diary - News
All news Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company
Recent developments include:
• Assembling a diverse portfolio of therapeutic peptides targeting clinical indications with high unmet need
• Launching collaborations with prestigious US academic groups
• Strengthening the leadership team
Lyon, France, November 14, 2018 - Alizé Pharma 3, a company specialized in developing therapeutic peptides for the treatment of rare endocrine and
metabolic diseases, today announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading
global rare disease company.
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree